The ANXA9 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ANXA9 gene in the near-haploid HAP1 cell line. This pooled loss-of-function model preserves genetic heterogeneity and avoids clonal selection, providing a physiologically relevant system for studying ANXA9-dependent processes. The gene product is a calcium-dependent phospholipid-binding protein implicated in membrane organization and signal transduction, and its disruption in this polyclonal format enables robust investigation of membrane biology and differentiation pathways without the constraints of monoclonal lines.
HAP1 is a human near-haploid cell line derived from the KBM-7 chronic myeloid leukemia (CML) line, which was originally isolated from a patient with CML. Its haploid karyotype simplifies genetic manipulation and reduces functional redundancy, making it a preferred host for CRISPR/Cas9-mediated gene disruption studies. The leukemic background retains key signaling features relevant to cancer biology, allowing the interrogation of gene function in both normal and malignant contexts. This cell line has been widely adopted for knockout screens and mechanistic studies due to its ease of culture and consistent growth characteristics.
ANXA9 functions as a calcium-dependent phospholipid-binding protein that mediates membrane-cytoskeleton interactions. It is activated by calcium influx and is transcriptionally regulated by SP1 and AP1 transcription factors. Downstream, ANXA9 promotes the expression of keratinocyte differentiation markers such as keratin 1 and loricrin, and it influences insulin secretion in pancreatic beta-cells. At the molecular level, ANXA9 interacts with membrane phospholipids, F-actin, and S100 proteins, thereby integrating calcium signals with cytoskeletal reorganization and membrane trafficking. These interactions position ANXA9 at a nexus of calcium signaling, actin dynamics, and differentiation programs.
In the HAP1 context, ANXA9 knockout leverages the haploid genome to eliminate gene copies completely, allowing clean dissection of its role in membrane-cytoskeleton cross-talk. The CML origin of HAP1 cells provides a relevant model to explore ANXA9’s contribution to cancer cell membrane biology, while the near-haploid state minimizes compensatory effects from related annexins. This model is particularly valuable for studying how calcium-dependent phospholipid binding impacts cell morphology, adhesion, and signaling in both leukemic and non-malignant pathways, including insulin secretion and epidermal differentiation.
Researchers can employ this polyclonal knockout pool in diverse experimental settings, including calcium-dependent phospholipid binding assays to assess membrane interaction, western blotting for keratin 1 and loricrin to monitor differentiation, and insulin secretion assays to model pancreatic function. Immunofluorescence and RT-qPCR further enable spatial and transcriptional analyses of ANXA9-dependent processes. These applications address key research areas such as type 2 diabetes, psoriasis, and cancer cell biology. For detailed protocols, validation data, or to inquire about custom products, please contact Ascent Research.
